Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Mutagenic chemotherapy and inhibition of mismatch repair as a strategy to boost anti-tumor immune response

Project description

Heating up cold colorectal tumours

Colorectal cancer responds well to immunotherapy only in a small group of patients whose tumours have defects in DNA repair. Most cases retain normal repair systems and remain ‘immune-cold’ without the immune system effectively recognising or attacking them. The ERC-funded CHIMERA project aims to change this by converting resistant colorectal tumours into ‘hot’ tumours that can respond to immunotherapy. Researchers will test a new inhibitor of DNA mismatch repair, together with selected chemotherapy drugs, in laboratory and animal models. By increasing tumour mutations and immune visibility, CHIMERA seeks to expand immunotherapy to many more patients and prepare this strategy for clinical trials.

Objective

In colorectal cancer (CRC), the efficacy of immunotherapy is currently limited to a small subgroup of tumors characterized by mismatch repair (MMR) deficiency. Conversely, little or no clinical benefit has been shown in the large majority of CRCs with MMR proficiency, which are accordingly defined as immune-cold tumors. Determining how to turn an immune-cold into a hot (immunotherapy responsive) tumor remains a major scientific challenge and an unmet clinical need.
Building on our recent demonstration that cytotoxic agents can increase tumor mutational burden and induce an immunogenic MMR deficient (MMRd)-like profile in preclinical CRC models, we devised CHIMERA as an ERC-2025-PoC initiative. CHIMERA leverages a validated in vitro and in vivo workflow to assess a first-in-class MMR inhibitor in combination with rationally selected cytotoxic agents, with the objective of converting MMR proficient (MMRp) cold tumors into an immunotherapy-responsive hot state. The project translates concepts generated within the ERC-ADG into a development program that integrates available drugs with novel molecules, thereby extending immunotherapy applicability beyond the current MMRd subgroup. Ultimately, CHIMERA is designed to consolidate proof-of-concept evidence for an innovative therapeutic strategy, laying the foundation for subsequent clinical testing and broader patient benefit in immuno-oncology.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

UNIVERSITA DEGLI STUDI DI TORINO
Net EU contribution
€ 150 000,00
Address
VIA GIUSEPPE VERDI 8
10124 Torino
Italy
Region
Nord-Ovest Piemonte Torino
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)